IP Library › Granted Patent US 9,592,222
Granted Patent B2
US 9,592,222 · App. 15/271,066 · Granted Mar 14, 2017

Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections

Inventors: Jason Allan Wiles (Hamden, CT); Qiuping Wang (Bethany, CT); Akihiro Hashimoto (Branford, CT); Godwin Pais (Hamden, CT); Xiangzhu Wang (Madison, CT); Venkat Gadhachanda (Hamden, CT); Avinash Phadke (Branford, CT); Milind Deshpande (Madison, CT); Dawei Chen (Middletown, CT)
Assignee: ACHILLION PHARMACEUTICALS, INC.
A61K31/4184A61K9/0053A61K9/20A61K31/4178A61K31/422A61K31/427A61K31/439A61K31/454A61K31/496A61K31/555A61K45/06C07D209/42C07D401/14C07D403/04C07D403/14C07D413/14C07D417/14C07D453/06C07D471/08C07D491/10C07D491/113C07D519/00C07F5/025C07F15/02C07F17/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,592,222
App. No.
15/271,066
Granted
Mar 14, 2017
Kind
B2
Abstract

The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D  (Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

Claims (7)

1. A pharmaceutical composition comprising from about 10 mg to about 1,000 mg of a compound of the structure:

or its pharmaceutically acceptable salt, in a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , which is suitable for oral delivery.

3. The pharmaceutical composition of claim 2 , which is a tablet.

4. The pharmaceutical composition of claim 2 , which is a capsule.

5. The pharmaceutical composition of claim 1 , which is suitable for parenteral delivery.

6. The pharmaceutical composition of claim 1 , which is suitable for topical delivery.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2016
From: WILES, JASON ALLAN; WANG, QIUPING; HASHIMOTO, AKIHIRO; PAIS, GODWIN; WANG, XIANGZHU; GADHACHANDA, VENKAT; DESHPANDE, MILIND; CHEN, DAWEI; PHADKE, AVINASH
To: ACHILLION PHARMACEUTICALS, INC.
Reel/Frame 039805/0715 →
Continuity (7)
Continuation 14972913 · Dec 17, 2015
Continuation 14328312 · Jul 10, 2014
Continuation 13482558 · May 29, 2012
Provisional Application 61567216 · Dec 6, 2011
Provisional Application 61504905 · Jul 6, 2011
Provisional Application 61490881 · May 27, 2011
Related Publication 20170007579A1 · Jan 12, 2017